ImmunityBio, Inc. (IBRX) Stock Analysis

ImmunityBio (IBRX) has shifted from a developmental biotech to an early commercial oncology company, with 2025 providing the first strong validation of both its product and go-to-market execution. ANKTIVA, a first-in-class IL‑15 superagonist complex, is differentiated from checkpoint inhibitors by directly stimulating NK cells and CD8+ memory T cells (“gas pedal”), aiming to deliver durable, memory-like anti-tumor immunity without the Treg expansion and toxicity limitations historically associated with older cytokines like IL‑2. In NMIBC, the company is leveraging a uniquely favorable backdrop: persistent BCG shortages and high unmet need for bladder-sparing therapies in BCG-unresponsive patients. Commercially, a permanent CMS J‑code in January 2025 removed reimbursement friction and helped drive sequential quarterly revenue growth to preliminary ~$113M for full-year 2025 (Q4 prelim ~$38.3M). The opportunity is meaningful but time-sensitive, as competitors (CG Oncology and J&J) are approaching with strong datasets and large commercial capabilities. Financially, the company remains loss-making and highly levered with substantial related-party debt and likely dilution via a 2026 convertible, while governance is concentrated with Dr. Patrick Soon‑Shiong controlling ~80% of equity/votes. The upside rests on NMIBC entrenchment plus pipeline optionality (notably NSCLC and first-line bladder) against these execution, leverage, and competitive risks.